NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 2026-11-01 19:08இன்று 36 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Q2 FY27 Investor Presentation: PAT Down 67% YoY to ₹1.63 Cr Despite 62% QoQ Revenue Rebound
Shree Ganesh Remedies released its Q2 & H1 FY27 investor presentation, reflecting continuing margin pressure despite a sequential operational pickup. Revenue from operations for Q2 FY27 stood at ₹23.29 Cr, declining 23% YoY but rebounding 62% QoQ from a weak Q1. EBITDA margin contracted sharply by 1,483 bps YoY to 16.9%, leading to a 67% YoY fall in PAT to ₹1.63 Cr. Construction of Block 7A is now complete and in trials, while commercial supplies for its Southeast Asian specialty chemicals project are targeted for Q1 FY28.
உச்சம் நம்பிக்கை
என்ன மாறியதுShree Ganesh Remedies filed its Q2 & H1 FY27 investor presentation detailing quarterly performance, CRAMS pipeline progress, and completion of Block 7A construction.
ஏன் இது முக்கியம்While sequential numbers show partial operational recovery after an exceptionally weak Q1, YoY profitability remains depressed due to weak European demand and input cost volatility, impacting high-margin CRAMS delivery.
📅 குறுகிய காலம்Sequential recovery in revenue provides some relief over Q1 lows, but significant margin compression will likely keep market sentiment cautious.
📈 நீண்ட காலம்Recovery hinges on expanding domestic intermediate volumes into export markets and the timely commercialization of the Southeast Asian CRAMS projects slated for Q1 FY28.
⚠ அபாய எச்சரிக்கைகள்
Volatile raw material costs depressing EBITDA margins
Prolonged softness in European demand and contract repricing pressure
👀 கவனிக்க வேண்டியவை
Track the commercial ramp-up and export traction of the two newly launched intermediates, alongside stabilization in gross margins and the commissioning timeline of Block 7A trials.
Shree Ganesh Remedies Ltd reported its unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. For the half-year, consolidated net cash generated from operating activities stood at Rs 1,765.61 lakhs (Rs 17.66 Cr), up from Rs 1,463.27 lakhs in the prior-year period. Net cash used in investing activities was Rs 523.30 lakhs, including capex of Rs 637.77 lakhs. The standalone subsidiary SGRL USA INC reported a marginal net loss after tax of Rs 0.47 lakhs for the quarter with zero revenue.
நடுத்தரம் நம்பிக்கை
என்ன மாறியதுSubmission of unaudited standalone and consolidated financial results and limited review report for Q2 and H1 ended September 30, 2026.
ஏன் இது முக்கியம்The cash flow statement reflects positive operating cash generation supporting continuous capex at the Ankleshwar facility, though CRAMS segment demand and contract repricing remain key drivers.
📅 குறுகிய காலம்Performance will be gauged against the subdued Q1 FY27 (June 2026) revenue base to check if sequential recovery in deliveries took place.
📈 நீண்ட காலம்Growth hinges on the expansion of the Ankleshwar facility and commercialization of complex chemistry projects for Japanese and European clients.
⚠ அபாய எச்சரிக்கைகள்
Softer European demand and domestic price realizations affecting CRAMS contracts
Customer concentration risk in export markets
👀 கவனிக்க வேண்டியவை
Investors should review detailed revenue and EBITDA performance in the full tables to assess if margins are stabilizing following contract repricing and European market softness.
SGRL Q2 FY27 Consolidated PAT at ₹1.63 Cr vs ₹4.56 Cr YoY; H1 Revenue Down 31%
Shree Ganesh Remedies reported standalone Q2 FY27 revenue from operations of ₹23.34 Cr (reported as 2,334.48 Lakhs), down 23.0% YoY compared to ₹30.32 Cr in Q2 FY26. Standalone net profit for the quarter dropped 64.2% YoY to ₹1.63 Cr (163.46 Lakhs) versus ₹4.56 Cr in the year-ago period, though it improved sequentially from ₹1.12 Cr in Q1 FY27. For H1 FY27, consolidated revenue fell 31.3% YoY to ₹37.70 Cr compared to ₹54.88 Cr in H1 FY26, reflecting persistent demand softness and contract repricing.
உச்சம் நம்பிக்கை
என்ன மாறியதுShree Ganesh Remedies announced its financial results for the quarter and half-year ended September 30, 2026, showing significant YoY operational contraction.
ஏன் இது முக்கியம்The performance underscores ongoing challenges in contract repricing and European demand softness, though Capex additions (CWIP up to ₹16.30 Cr) indicate continued investment for post-FY26 recovery.
Q2 Standalone Revenue: ₹2,334.48 லட்சம்Q2 Standalone Net Profit: ₹163.46 லட்சம்H1 Standalone Revenue: ₹3,770.47 லட்சம்H1 Standalone Net Profit: ₹275.47 லட்சம்Capital Work-in-Progress: ₹1,630.06 லட்சம்
📅 குறுகிய காலம்Likely subdued sentiment following a 64% YoY drop in quarterly net profit, despite sequential margin improvement over Q1 FY27.
📈 நீண்ட காலம்Performance remains tied to the success of its transition from commodity intermediates to niche specialty chemicals and execution of the expanded Ankleshwar capacity.
⚠ அபாய எச்சரிக்கைகள்
Substantial YoY revenue and margin contraction due to contract repricing and weak global demand
Inventory build-up with inventories rising to ₹33.53 Cr as of Sep 2026 from ₹24.01 Cr in Mar 2026
👀 கவனிக்க வேண்டியவை
Track the commercialization timeline of the Ankleshwar expansion and final approvals on the Japanese specialty chemicals project, which are critical to reversing revenue contraction.
Q1FY27 Revenue down 42% YoY; Management moderates FY27 growth guidance
Shree Ganesh Remedies reported a weak Q1FY27 with revenue falling 42% YoY to ₹14.36 Cr and PAT declining 68% YoY to ₹1.12 Cr. The downturn was primarily caused by subdued European demand and the termination of a marketing agreement with an EU distributor due to non-performance. Consequently, management has moderated its earlier guidance of 'non-linear growth' for FY27, now expecting a recovery only in the second half of the year. Despite the short-term setback, the company is continuing its Ankleshwar site expansion and Dahej land acquisition for future capacity.
உச்சம் நம்பிக்கை
என்ன மாறியதுSignificant quarterly performance decline and a formal moderation of the FY27 growth outlook from 'non-linear' to recovery-based.
ஏன் இது முக்கியம்The company is transitioning from a distributor-led model to direct customer engagement in the EU, which creates a short-term volume gap but aims for higher long-term control and margins.
Q1FY27 Revenue: ₹14.36 கோடிYoY Revenue Change: -42%Q1FY27 PAT: ₹1.12 கோடிYoY PAT Change: -68%EBITDA லாப வரம்பு: 23.3%Debt to Equity (FY26): 0.18
📅 குறுகிய காலம்Negative sentiment is expected due to the sharp earnings miss and the guidance downgrade, with recovery unlikely before H2FY27.
📈 நீண்ட காலம்The structural shift towards niche specialty chemicals and direct EU sales remains the focus, but long-term value depends on the successful execution of the Ankleshwar and Dahej expansions.
⚠ அபாய எச்சரிக்கைகள்
Geopolitical uncertainty affecting EU demand
Distributor transition risks
Volatility in raw material markets
👀 கவனிக்க வேண்டியவை
Monitor the restoration of volumes in the EU market following the distributor termination and the commissioning timeline of 'Block 7' at the Ankleshwar site. Watch for the start of revenue contributions from South-East Asian CRAMS projects in H2FY27 as a recovery signal.
68% PAT drop in Q1FY27; SGRL moderates FY27 growth guidance amid European headwinds
Shree Ganesh Remedies Ltd (SGRL) reported a weak Q1FY27 with revenue declining 42% YoY to ₹14.36 Cr and PAT falling 68% YoY to ₹1.12 Cr. The performance was severely impacted by subdued demand in Europe and the termination of a non-performing distributor agreement, leading management to withdraw its earlier guidance of 'non-linear growth' for FY27. EBITDA margins contracted significantly to 23.3% from 29.6% YoY, reflecting lower operating leverage and raw material volatility. The company expects a recovery in H2FY27 driven by new CRAMS projects and direct customer engagement in Europe.
உச்சம் நம்பிக்கை
என்ன மாறியதுSGRL has shifted from a distributor-led model to direct sales in Europe following a contract termination and has officially lowered its growth expectations for FY27.
ஏன் இது முக்கியம்The sharp earnings miss and guidance downgrade are significant for a company trading at a high P/E of 44.9, as it indicates a temporary break in the growth trajectory and margin profile.
📅 குறுகிய காலம்The stock is likely to face downward pressure in the short term due to the substantial earnings miss and the withdrawal of aggressive growth guidance.
📈 நீண்ட காலம்The long-term outlook depends on the company's ability to restore volumes through direct sales and the successful execution of its specialty chemicals expansion at the Ankleshwar site.
⚠ அபாய எச்சரிக்கைகள்
Geopolitical uncertainty affecting European demand
Execution risk in transitioning to direct sales
Margin pressure from raw material volatility
Guidance downgrade
👀 கவனிக்க வேண்டியவை
Investors should monitor the timeline for the commissioning of Block 7 and the progress of direct customer acquisition in Europe to replace the terminated distributor. The key recovery trigger will be the commercialization of CRAMS projects in South-East Asia, expected in H2FY27.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Shree Ganesh Remedies (SGRL) reported a weak set of numbers for Q1 FY27, with standalone revenue falling 41.8% YoY to Rs 14.36 Cr. Net profit saw a sharper decline of 66.7% YoY to Rs 1.15 Cr, down from Rs 3.45 Cr in the year-ago period. The results reflect the company's previously stated 'year of consolidation' amid softer demand in Europe and contract repricing in its CRAMS business. The US subsidiary remains non-material with zero revenue for the quarter.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has transitioned into a significant earnings contraction phase, with Q1 revenue representing only ~13% of the previous TTM revenue, down from a typical ~25% run rate.
ஏன் இது முக்கியம்The sharp decline in profitability confirms the impact of external headwinds like European market softness and competitive pricing pressures on the company's high-margin CRAMS model.
Revenue (Q1 FY27): Rs 14.36 கோடிNet Profit (Q1 FY27): Rs 1.15 கோடிYoY Revenue Growth: -41.8%YoY PAT Growth: -66.7%Q1 வருவாய் vs TTM வருவாய்: 13.2%
📅 குறுகிய காலம்The stock is likely to face downward pressure in the short term as the market reacts to the significant miss in both revenue and profitability.
📈 நீண்ட காலம்Structural recovery depends on the commercialization of specialty chemical projects for Japanese clients and the completion of the Ankleshwar expansion by mid-2026.
⚠ அபாய எச்சரிக்கைகள்
Sharp revenue contraction
Contract repricing pressure
Soft demand in European markets
High inventory volatility
👀 கவனிக்க வேண்டியவை
Investors should monitor the stabilization of contract repricing and the execution timeline of the Ankleshwar site expansion, which is critical for growth post-FY26.
Shree Ganesh Remedies reported a weak set of numbers for Q1 FY27, with revenue from operations falling 41.8% YoY to Rs 14.36 crore. Net profit plummeted 67.2% YoY to Rs 1.13 crore, down from Rs 3.45 crore in the same period last year. Sequentially, the performance was even more subdued, with revenue dropping 56.7% from Rs 33.20 crore in Q4 FY26. This sharp contraction aligns with management's earlier guidance of FY26 being a 'year of consolidation' amid softer European demand and contract repricing.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has reported a significant year-on-year and sequential contraction in both its top-line and bottom-line for the first quarter of FY27.
ஏன் இது முக்கியம்The results confirm the immediate impact of softer demand in Europe and downward contract repricing, which are currently outweighing the company's technical expertise in complex chemistry.
📅 குறுகிய காலம்The stock is likely to face negative sentiment in the short term due to the sharp decline in quarterly profitability and revenue.
📈 நீண்ட காலம்Long-term recovery depends on the successful shift toward niche specialty chemicals and the commercialization of new capacity at the Ankleshwar site.
⚠ அபாய எச்சரிக்கைகள்
Significant revenue contraction
Sharp decline in net profit margins
Exposure to softer demand in European markets
👀 கவனிக்க வேண்டியவை
Investors should monitor the stabilization of CRAMS contract pricing and the progress of the Ankleshwar site expansion, which is key to post-FY26 growth. Watch for updates on the specialty chemicals project for the Japanese client expected by mid-2026.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
